Leanne Kline
Family Medicine · Brevard, NCNPI 1922393842
Payments from drug & device makers
Across 146 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$312
- AstraZeneca$268
- AbbVie$222
- Lilly USA, LLC$189
- Amgen$174
- Johnson & Johnson$140
- plus $887 from 18 others
What the payments were for
- Food & beverage$2,16999%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $312 |
| AstraZeneca | 16 | $268 |
| AbbVie(2 entities) | 13 | $222 |
| Lilly USA, LLC | 12 | $189 |
| Amgen | 11 | $174 |
| Johnson & Johnson | 8 | $140 |
| Boehringer Ingelheim | 9 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Pfizer | 5 | $81 |
| Bayer | 4 | $80 |
| Novartis | 3 | $77 |
| Amarin Pharma, Inc. | 4 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Merck | 3 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| GSK | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
How this compares
$2,190 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $97,099 |
| EliquisApixaban | 66 | $76,426 |
| JardianceEmpagliflozin | 43 | $47,066 |
| TrulicityDulaglutide | 23 | $45,499 |
| MounjaroTirzepatide | 27 | $40,230 |
| LinzessLinaclotide | 26 | $40,090 |
| XareltoRivaroxaban | 25 | $38,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $33,975 |
| Repatha SureclickEvolocumab | 37 | $30,212 |
| RybelsusSemaglutide | 15 | $26,890 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $22,494 |
| MyrbetriqMirabegron | 32 | $19,496 |
| FarxigaDapagliflozin Propanediol | 18 | $18,440 |
| VraylarCariprazine Hcl | 12 | $17,166 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $312 | $123,98969 claims |
| PfizerEliquis, Premarin | $81 | $90,61497 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $189 | $85,72950 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $128 | $69,15774 claims |
| AbbVieLinzess, Vraylar, Synthroid | $222 | $63,698119 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $26 | $56,46972 claims |
| Johnson & JohnsonXarelto | $140 | $38,83825 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $268 | $33,32032 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $19,49632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Brevard
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.